Treatment of Parkinson's disease with L-dopa: a current appraisal.
Interest in l-dopa therapy for Parkinson's disease has been considerably enhanced since the recent release of this drug to all medical practitioners. Our experience in the use of l-dopa in 83 patients who have been treated during the past 22 months is presented to provide a practical approach to the administration of l-dopa. Many parkinsonian patients can be treated advantageously on an outpatient basis without the need for initial hospitalization. Some of the common side effects of l-dopa administration can be averted or controlled by a cautious and slow build-up to the optimal dosage level. In the majority (78%) of parkinsonian patients who had been carefully selected for treatment the drug had a beneficial effect on akinesia and rigidity. In the remainder, therapy had to be discontinued because of undesirable side effects or a limited response.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy
D004295:Dihydroxyphenylalanine